Irritable bowel syndrome: pathophysiological and clinical issues
Abstract
The aim of review. To discuss the issues of etiology, pathogenesis, clinical presentation and differential diagnostics of irritable bowel syndrome (IBS).
Summary. At irritable bowel syndrome there are series of structural changes interconnected with each other, built into logic chain, that ends by development of symptoms. However it remains not quite clear, whether they determine severity and origin of clinical symptoms, as well as the degree of involvement of each of the basic known pathogenic mechanisms in development of symptoms in given patient is insufficiently clear. The long-term analysis of IBS symptoms has not led to development of clear diagnostic criteria due to both objective causes (frequent, up to 87% combination of various functional disorders) and due to possible identity of complaints in patients to IBS, clostridial infection, microscopic colitis, celiac sprue. Lack of scrutiny of etiology, pathogenesis, clinical presentation determines low treatment efficacy of such patients.
Conclusion. Treatment of patients will allow to optimize further investigations of certain etiological, pathogenic factors, to carry out differential diagnostics of IBS more clearly.
About the Authors
V. T. Ivashkin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Ye. A. Poluektova
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Poluektova Yelena A – MD, leading research associate, Scientific and educational clinical center of innovative therapy, physician of department of chronic bowel and pancreatic diseases
119991, Moscow, Pogodinskaya street, 1, bld 1
References
1. Белхушет С. Роль психовегетативных и нейрофизиологических факторов в формировании боли при синдроме раздраженного кишечника: Дис. канд. мед. наук. М., 2007.
2. Бескова Д.А. Клинико-психологические характеристики внешней и внутренней границ телесности (на модели соматоформных расстройств): Дис. канд. мед. наук. М., 2006.
3. Беспалов А.Ю., Звартау Э.Э. Нейропсихофармакология антагонистов NMDA-рецепторов. СПб: Невский диалект, 2000; Скребицкий В.Г. Синаптическая пластичность как проблема нейрофизиологии. Вестник РФФИ 2004; 4:65-81.
4. Ивашкин В.Т. Основные понятия и положения фундаментальной иммунологии. Рос журн гастроэнтерол гепатол колопроктол 2008; 18(4):4-14.
5. Ивашкин В.Т. Синдром раздраженной кишки: Практическое руководство для врачей. М.: РГА, 1999:28 с.
6. Кернберг О.Ф. Тяжелые личностные расстройства. Стратегии психотерапии. Пер. с англ. М.И. Завалова/ Под ред. М.Н. Тимофеевой. М.: Независимая фирма «Класс», 2000.
7. Колесников Д.Б. Синдром раздраженной толстой кишки (психосоматические соотношение типология, терапия): Автореф. дис. канд. мед. наук. М., 2000.
8. Крыжановский Г.Н. Дизрегуляционная патология: Руководство для врачей и биологов. М.: Медицина, 2002.
9. Курбатова А.А. Патогенетическое и клиническое значение системы цитокинов и клаудинов у больных с синдромом раздраженного кишечника: Дис. канд. мед. наук. М., 2013.
10. Маев И.В., Барденштейн Л.М., Антоненко О.М. и др. Психосоматические аспекты заболеваний желудочно-кишечного тракта. Клин мед 2002; 80(11):8-13.
11. Маев И.В., Кучерявый Ю.А., Черёмушкин С.В. Эволюция представлений о синдроме раздраженного кишечника. М., 2013.
12. Мак-Вильямс Нэнси. Психоаналитическая диагностика: Понимание структуры личности в клиническом процессе. М.: «Класс», 1998. 480 с.
13. Микляева А.В., Румянцева П.В. Социальная идентичность личности: содержание, структура, механизмы формирования: Монография. СПб: Изд-во РГПУ им. А.И. Герцена, 2008:8-47.
14. Новиков А.В., Яхно Н.Н. Невропатическая боль, патофизиологические механизмы и принципы терапии. Рус мед журн 2001; 9(7-8):318-27.
15. Осадчук А.М., Балашов А.В. Прогностические критерии клинических форм синдрома раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол 2008; 18(5):61.
16. Павленко С.С. Эпидемиология боли. Неврол журн 1999; 4(1):41.
17. Парфенов А.И. Синдром раздраженного кишечника: стандарты диагностики и лечения. Consilium medicum 2005; 5(3):25-7.
18. Парфенов А.И., Ручкина И.Н. Синдром раздраженного кишечника. Мед вестник 2006; 16:359.
19. Полуэктова Е.А. Некоторые особенности патогенеза, клиники, диагностики и лечения синдрома раздраженного кишечника: Дис. канд. мед. наук. М., 2002.
20. Полуэктова Е.А. Синдром раздраженного кишечника (СРК) от патогенеза к лечению. Южно-Рос мед журн 2004; 4:56-62.
21. Полуэктова Е.А., Шептулин А.А., Ивашкин В.Т., Юрманова Е.Н., Белхушет С., Бескова Д.А. Возможности улучшения результатов лечения больных с синдромом раздраженного кишечника. Клин перспективы гастроэнтерол гепатол 2006; 3:29-37.
22. Рупчев Г.Е. Психологическая структура внутреннего телесного опыта при соматизации (На модели соматоформных расстройств): Дис. канд. психол. наук. М., 2001.
23. Саркисов Д.С. Следует, наконец, отказаться от понятий «функциональная болезнь», «функциональная патология» (По поводу статьи А.М. Ногаллера «Следует ли клиницистам отказаться от понятий функциональной патологии?»). Клин мед 1998; 3:64-7.
24. Собчик Л.Н. Введение в психологию индивидуальности. М.: ИПП-ИСП, 2000:44-55.
25. Хаитов Р.М., Игнатьева Г.А., Сидорович И.Г. Иммунология. Норма и патология. М.: Медицина, 2010.
26. Царегородцева Т.М., Серова Т.И., Ильченко Л.Ю. и др. Прогностическое значение цитокинов при хронических заболеваниях органов пищеварения. Мед иммунология 2002; 4(2):167.
27. Шептулин А.А. Римские критерии-III синдрома раздраженного кишечника: что мы ожидали и что мы увидели? Рос журн гастроэнтерол гепатол колопроктол
28. ; 17(2):63-8.
29. Юрманова Е.Н. Отдаленные результаты лечения и прогноз пациентов с синдромом раздраженного кишечника: Дис. канд. мед. наук. М., 2007.
30. Ballou SK, Keefer L. Multicultural considerations in the diagnosis and management of irritable bowel syndrome: a selective summary. Eur J Gastroenterol Hepatol 2013; 25:1127-33.
31. Barbara J., Stanghellini V., de Giorgio R., et al. Activated mast cells in proximity to colonic nerves correlates with abdominal pain in irritable bowel syndrome. Gastrornterology 2004; 126:693-702.
32. Bertiaux-Vandaële N., Youmba S.B., Belmonte L., et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am. J. Gastroenterol. 2011; 106:2165-73.
33. Besedovsky H., del Rey A., Sorkin E., et al. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986; 233:652-4.
34. Bhuiyan M., Majamder T., Raihan A. Histopatological alteration in post-infectious irritable bowel syndrome (PI – IBS) in a group of Bangladeshi population: a prospective observational study. Gut 2009; 58:182.
35. Blanco P., Palucka A.K., Pascual V., et al. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008; 19(1):41-52.
36. Bliss T.V.P., Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol 1973; 334:475-91.
37. Brint E.K., et al. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011; 106:329-36.
38. Brookoff D. State medical boards and pain management: Commentary. J Pain Symptom Management 1998; 15(6):381-2.
39. Camilleri M., et al. Measurement of serum 7alphahydroxy-4-cholesten-3-one (or7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatographytandem mass spectrometry. Neurogastroenterol Motil 2009; 21:734-43.
40. Chadwick V.S., Chen W., Shu D., et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122(7):1778-83.
41. Chang F., Ching-Liang L., Chih-Yen C., et al. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol 2007; 22:2266-72.
42. Clarke G., McKernan D.P., et al. A Distinct profile of tryptophan metabolism along the kynurenine pathway downstream of toll-like receptor activation in irritable bowel syndrome. Front Pharmacol 2012; 3:90.
43. Connor T.J., Leonard B.E. Depression, stress and immunological activation: The role of cytokines in depressive disorders. Life Sciences 2000; 62:583-606.
44. Creed F. Relationship between IBS and psychiatric disorder. In: Irritable bowel syndrome / Eds. M. Camilleri, R.C. Spiller, 2002:45-54.
45. Cremon C., Gargano L., Morselli-Labate A.M., Santini D., Cogliandro R.F., de Giorgio R., Stanghellini V., Corinaldesi R., Barbara G. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol. 2009;104:392-400.
46. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behavior Immunity 2001; 15:7-24.
47. De Giorgio R., Accarino A., Azpiros F., et al. Mast cell neuromuscular involvement in patients with severe gastrointestinal dysmotility (SGID). Gut 2007; 56:A18.
48. Dinan T.G., Quigley E.M., Ahmed S.M., et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130(2):304-11.
49. Dlugosz A., Lindberg G. The expression of toll-like receptor 4 in colon mucosa is as up-regulated in irritable bowel syndrome as it is in inflammatory bowel disease. Gut 2010; 59:A31.
50. Drossman D.A. Integrated approach to irritable bowel syndrome. World Gastroenterol News 2004; 9(Iss. 1):11-2.
51. Dunlop S.P., Jenkins D., Neal K.R., Spiller R.C. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125(6):1651-9.
52. Duran F.G., Castellano V., Ciriza C., et al. Relationship between irritable bowel syndrome and colonic inflammation. Gut 2008; 57: A 377.
53. Eriksson E.M., Andren K.I., Eriksson H.T., et al. Irritable bowel syndrome subtypes differ in body awareness, psychological symptoms and biochemical stress markers. World J Gastroenterol 2008; 14(31):4889-96.
54. Foley S.J., Singh G., Lau LC., Walls A.F., et al. Depressed serotonin transporter in platelets of patients with IBS and diarrhea (IBS-D) and coeliac disease: a biomarker a low grade inflammation in duodenal biopsies. Gut 2008; 57: A 97.
55. Freud S. 55 The neuropsychoses of defence standart edition (SE), Vol. 3. London: Hogart press, 1894.
56. Gecse K., Roka R., Sera E., Rosztoczy A., et al. Gut permeability in patients with irritable bowel syndrome and inactive ulcerative colitis. Gut 2009; 58: A 178.
57. Gonzales Gamarra R.G., Ruiz Sánchez J.G., León Jiménez F., Cubas Benavides F., Díaz Vélez C. Prevalence of irritable bowel syndrome in the adult population of the city of Chiclayo in 2011. Rev Gastroenterol Peru 2012; 32:381-6.
58. Goral V., Kucukoner M., Buyukbayram H. Mast cells count and serum cytokine levels in patients with irritable bowel syndrome. Hepatogastroenterology 2010; 57(101):751-4.
59. Guilarte M., Santos J., de Torres I., et al. Diarrhoeapredominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56(2):203-9.
60. Guilera M., Balboa A., Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 2005; 100:1174-84.
61. Gwee K.A., Lu C.L., Ghoshal U.C. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J Gastroenterol Hepatol 2009; 24:1601-7.
62. Howard Mertz altered CNS processing of visceral pain in IBS in irritable bowel syndrome. Diagnosos and treatment / Eds. M. Camilleri, R.C. Spiller, 2002.
63. Ihan A. Introduction in modern immunology relevance for neuropschiatry. Acta Neuropschiatria 2008; 20:1-2.
64. Khan I., Collins S.M. Is there an inflammatory basis for a subset of patients presenting with diarrhoea in the irritable bowel syndrome? Gastroenterology 1994; 105:A523.
65. Koloski N.A., et al. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012; 61:1284-90.
66. Kong W.M., Gong J., Dong L., Xu J.R. Changes of tight junction claudin-1,-3,-4 protein expression in the intestinal mucosa in patients with irritable bowel syndrome. Nan Fang Yi Ke Da Xue Xue Bao 2007; 27(9):1345-7.
67. Krogsgaard L.R., Engsbro A.L., Bytzer P. The epidemiology of irritable bowel syndrome in Denmark. A population-based survey in adults 50 years of age. Scand J Gastroenterol 2013; 48:523-9.
68. Labow B.I., Souba W.W. Glutamine. World J Surg 2000; 24(12):1503-13.
69. Lee B.J., Bak Y.T. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 2011; 17(3):252-66.
70. Lee H.J., Lee S.Y., Choi J.E., et al. G protein beta3 subunit, interleukin-10, and tumor necrosis factor-alpha gene polymorphisms in Koreans with irritable bowel syndrome. Neurogastroenterol Motil 2010; 22(7):758-63.
71. Lee Y.Y., Waid A., Tan H.J., Chua A.S., Whitehead W.E. Rome III survey of irritable bowel syndrome among ethnic Malays. World J Gastroenterol 2012; 18:6475-80; discussion p. 6479.
72. Liebregts T., Adam B., Bredack C., Röth A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132:913-20.
73. Lobo B., Vicario M., Martinez C., et al. Clinical improvement in IBS after disodium cromoglycate involves mast cell-mediated toll-like receptor signaling downregulation. Gut 2010; 59: A 52.
74. Locke G.R. 3rd, et al. Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol 2004; 99:350-7.
75. Longstreth G.F., Thompson W. Grant, Chey William D., Houghton Lesley A., Mearin Fermin, Spiller R.C. Funcional bowel disorders. Gastroenterology 2006; 130:1490-1.
76. Lucas A., Cobelens P.M., Kavelaars A., et al. Disturbed in vitro adrenergic modulation of cytokine production in inflammatory bowel diseases in remission. J Neuroimmunol 2007; 182(1):195-203.
77. Maddock C., Baita A., Orru M.G., et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferonalpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004; 18:41-6.
78. Maier S.F., Watkins L.R. Cytokines for psychologists: Implications of bidirectional immune-tobrain communication for understanding behavior, mood, and cognition. Psychological Review 1998; 105:83-107.
79. Makino S., Hasimoto K., Gold P.W. Multiple feedback mechanisms activating corticotropin-releasing hormone system in the brain during stress. Pharmacol Biochem Behav 2002; 73:147-58.
80. Martinez C., Vicario M., Lobo B., et al. Mucosal mast cell-mediated tight junction impairment correlates to symptom severity in diarrhea-prone irritable bowel syndrome patients. Gut 2010; 59: A 18.
81. Miller, A.H., Pariante C.M., Pearce B.D. Effects of cytokines on glucocorticoid receptorexpression and function. Adv Exp Med Biol 1999; 461:107-16.
82. Montagnani M., et al. Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients
83. with adult-onset idiopathic bile acid malabsorption. Scand J Gastroenterol 2001; 36:1077-80.
84. Morris R.G.M., Davis M. The role of NMDA receptors in learning and memory. In the NMDA receptors, Ed. 2 / Eds. Collingridge G.K., Watkins J.C. Oxford: Oxford University Press, 1994:340-75.
85. Motzer S.A., Jarrett M., Heitkemper M.M., et al. Natural killer cell function and psychological distress in women with and without irritable bowel syndrome. Biol Res Nurs 2002; 4(1):31-42.
86. Öhman L., Isaksson S., Lindmark A.C., et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104(5):1205-12.
87. Öhman L., Lindmark A.C., Isaksson S., et al. Increased TLR2 expression on blood monocytes in irritable bowel syndrome patients. Eur J Gastroenterol Hepatol 2012; 24(4):398-405.
88. Ortiz-Lucas M., Saz-Peiró P., Sebastián-Domingo J.J. Irritable bowel syndrome immune hypothesis. Part one: the role of lymphocytes and mast cells. Rev Esp Enferm Dig 2010; 102(11):637-47.
89. Osler W. The principles and practice of medicine: designed for the use of practitioners and students of medicine, New York: D Appleton and company.
90. Piche T., Saint-Paul M.C., Dainese R., MarineBarjoan E., Iannelli A., Montoya M.L., Peyron J.F., Czerucka D., Cherikh F., Filippi J., et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008; 57:468-73.
91. Pimentel M., Chow E.J., Lin H.C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95(12):3503-6.
92. Pimentel M., Chow E.J., Lin H.C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98(2):412-9.
93. Pyleris E., Giamarellos-Bourboulis E.J., Koussoulas B. Prevalence of small intestinal bacterial overgrowth in a greek cohort: relationship with irritable bowel syndrome. Gut 2010; 59: A 19.
94. Romero-Valdovinos M., Gudiño-Ramírez A., ReyesGordillo J. Interleukin-8 and -10 gene polymorphisms in irritable bowel syndrome. Mol Biol Rep 2012; 39:8837-43.
95. Scully P., McKernan D.P., Keohane J., et al. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010; 105(10):2235-43.
96. Spiller R.C. Post-infectious IBS in irritable bowel syndrome. Diagnosis and treatment / Eds. M. Camilleri, R.C. Spiller, 2002:85-94.
97. Thompson W.G., Longstreth G.L., Drossman D.A., et al. Functional bowel disorders. In: Rome II: The functional gastrointestinal disorders. Diagnosis, pathophysiology and treatment. A multinational consensus / Eds. Drossman D.A., Corazziari E., Talley N.J., et al. Lawrence, KS: Allen Press, 2000.
98. Turnbull A.V., Rivier C.L. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999; 79:1-71.
99. Walters J.R., et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepathol 2009; 7:1189-94.
100. Wang L.H., Fang X.C., Pan G.Z. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53(8):1096-101.
101. Wong B.S., et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2012;10:1009-15.
102. Wong H.Y., Chang Lin. Stress and the gut: Central influences. In: A basis for understanding functional diseases / Eds. R. Spiller, D. Grundy Blackwell, 2004:45-51.
Review
For citations:
Ivashkin V.T., Poluektova Ye.A. Irritable bowel syndrome: pathophysiological and clinical issues. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(1):4-16. (In Russ.)
Views:
176
Email this article 
